Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: Results of a randomized, multicentre, comparative study

British Journal of Dermatology

Volumn 159, Issue 6, 2008, Pages 1348-1356

  Thaci D ^a   Reitamo, S ^b   Gonzalez Ensenat, M A ^c   Moss, C ^d   Boccaletti, V ^e   Cainelli, T ^f   Van Der Valk, P ^g   Buckova, H ^h   Sebastian, M ⁱ   Schuttelaar, M L ^j   Ruzicka, T ^k  

^a GOETHE UNIVERSITY   (Germany)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁱ Group Practice   (Germany)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

0.03 tacrolimus ointment; Atopic dermatitis; Children; Disease control; Proactive therapy

Indexed keywords

TACROLIMUS;

ADOLESCENT; APPLICATION SITE INFECTION; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BRONCHOPNEUMONIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GASTROENTERITIS; HERPES SIMPLEX; HUMAN; IMPETIGO; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SKIN PAPILLOMA; SLEEP APNEA SYNDROME; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; EMOLLIENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TACROLIMUS; TREATMENT OUTCOME;

EID: 56549121036     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08813.x     Document Type: Article

References (32)

1. Darsow U, Luebbe J, Taieb JA et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005 19 : 286 95.
2. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006 118 : 152 69.
3. Alomar A, Berth-Jones J, Bos JD et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 151 (Suppl. 70 3 27.
4. Mihm MC, Sotor NA, Dvora HF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976 67 : 305 12.
5. Wollenberg A, Wen S, Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric miromethod. Catometry 1999 37 : 147 55.
6. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002 147 : 528 37.
7. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003 326 : 1367 72.
8. Lubach D, Bensmann A, Bornemann U. Steroid induced dermal atrophy. Investigations on discontinuous application. Dermatologica 1989 179 : 67 72.
9. Bos JD, Sillevis Smitt JH. Atopic dermatitis. J Eur Acad Dermatol Venereol 1996 7 : 101 14.
10. Boguniewicz M, Fiedler VC, Raimer S et al. A randomized vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998 102 : 637 44.
11. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 44 (Suppl. 1 S58 64.
12. Reitamo S, Harper J, Bos JD et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004 150 : 554 62.
13. Reitamo S, Van Leent EJM, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002 109 : 539 46.
14. Paller A, Eichenfield LF, Leung DYYM et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 44 (Suppl. 1 S47 57.
15. Ashcroft DM, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005 330 : 516.
16. Hanifin JM, Paller AS, Eichenfield L et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005 53 (Suppl. 187 94.
17. Fleischer AB, Ling M, Eichenfield L et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002 47 : 562 70.
18. Rubins A, Gutmane R, Valdmane N et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005 125 : 68 71.
19. Harper J, Smith C, Rubins A et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005 124 : 695 9.
20. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980 92 (Suppl. 44 7.
21. Rajka G, Langeland T. Grading of severity of atopic dermatitis. Acta Derm Venereol 1989 144 (Suppl. 13 14.
22. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
23. Lewis Jones MS, Finlay AY, Dykes P. The Infants' Dermatitis Quality of Life Index. Br J Dermatol 2001 144 : 104 10.
24. ©): initial validation and practical use. Br J Dermatol 1995 132 : 942 9.
25. Hodges JR, Lehmann EL. Estimates of location based on rank tests. Ann Math Stat 1963 34 : 598 611.
26. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : 1 8.
27. Kapp A, Papp K, Bingham A et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002 110 : 277 84.
28. Remitz A, Harper J, Rustin M et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 2007 87 : 54 61.
29. Hofman T, Cranswick N, Kuna P et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006 91 : 905 10.
30. Callen J, Chamlin S, Eichenfield LF et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007 156 : 203 21.
31. Leung DY, Boguniewicz M, Howell MD et al. New insights into atopic dermatitis. J Clin Invest 2004 113 : 651 7.
32. Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001 44 : S65 72.